GILDBy Calypso Research7 min read

Gilead Sciences (GILD) Q4 2025 Earnings Analysis

Gilead's YES2Gains: $7.9B Revenue on the Rise

Key Takeaways

Gilead Sciences (GILD) reported Q4 2025 earnings with revenue of $7.9B, representing a +4.7% year-over-year change. The stock moved +5.8% on earnings day.

The bull case: A diversified HIV and oncology pipeline led by YES2GO, long-acting lenacapavir regimens, Trodelvy expansion, and Anidocel can drive sustained mid- to high-single-digit growth with robust margins and limited LOE risk into the 2030s.

The bear case: Policy headwinds, competitive pressure in cell therapy and ADCs, execution risk on multiple high-expectation launches (YES2GO, long-acting HIV, Trodelvy, Anidocel), and potential BD missteps could cap growth and compress returns despite a seemingly full pipeline.

Financial Highlights

  • Revenue: $7.9B (+4.7% YoY)
  • Gross Profit: $6.9B (86.8% margin, +7.7% YoY)
  • Operating Income: $3.0B (37.4% margin, +5.0% YoY)
  • Net Income: $2.2B
  • TTM Revenue: $29.4B

Stock Performance

  • Earnings Day Move: +5.8%
  • Year-to-Date: +23.2%
  • 1-Year Return: +34.9%
  • vs. S&P 500 (since earnings): +18.0%
  • vs. Nasdaq (since earnings): +20.9%

View live GILD data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Gilead Sciences's Q4 2025 earnings call:

YES2GO ramp, 2026 $800M guide, and impact on Descovy PrEP

Sentiment: Positive

"Given our expectations for a steady, durable, and long-term build in sales, we expect full-year 2026 YES2GO revenue of approximately $800 million compared to $150 million in 2025, highlighting that YES2GO is well on its way to achieving blockbuster status." — Johanna Mercier
"We do believe that YES2GO is going to be the strong performer... in 2026, we believe that Descovy continues to grow through in 2026... and over time, of course, that will erode as YES2GO takes a leading share in HIV prevention." — Johanna Mercier

Long-acting HIV treatment/prevention strategy (lenacapavir + GS‑3242, bnAbs, once‑yearly PrEP)

Sentiment: Positive

"Specifically for the once every six months, I also want to point out that we have two programs in development... 3242 is obviously a long-acting INSTI. We firmly believe that an integrase inhibitor is important in this combination, and think that also sets it apart from some of the other options that are out there." — Dietmar Berger
"We've been very clear with the market research that we've seen that frequency or less frequency in the HIV PrEP setting specifically is the most important... YES2GO being such an important innovation... let alone the potential of going to every twelve months, really would potentially attract a larger population." — Johanna Mercier

Anidocel’s launch trajectory and competitive positioning in multiple myeloma CAR‑T

Sentiment: Positive

"The market for fourth-line multiple myeloma is a $3.5 billion market... we expect over time to become the market leader given our excellent efficacy profile and differentiated safety profile, in particular with the delayed neurotoxicity in enterocolitis." — Cindy Perettie
"We will have the ability to serve the market at launch. With 99% reliability and sixteen-day turnaround time, which, again, is very differentiated from the existing products on the market today." — Cindy Perettie

Trodelvy expansion into first-line TNBC and other tumors (endometrial, NSCLC)

Sentiment: Positive

"Trodelvy is now the only ADC that is recommended both in first-line PD-L1 positive and PD-L1 negative metastatic TNBC as well as second-line setting... it's about double or so if you think about second-line setting into the first-line setting, there's about ten thousand or so women in the first-line setting." — Johanna Mercier
"We are primarily intrigued about endometrial because of the earlier study... where we saw a median OS of fifteen months... we feel, you know, with data like that, this would be a really important addition to the treatment options for second-line endometrial cancer patients." — Dietmar Berger

Capital allocation & BD appetite given a “full” pipeline and no LOEs until 2036

Sentiment: Positive

"We have up to 10 launches now either ongoing or to be introduced over between now and 2027... as we approach later-stage acquisitions, we do it in the context of the fact that we have the most robust clinical and launch pipeline in our company's history with no major LOEs until 2036." — Daniel O'Day
"We would like to add synergistic derisk late-stage assets that will further, you know, I define it as turbocharge our top-line growth, and drive even more outsized bottom-line growth. And we will be disciplined in that, but we've been very active in this space." — Andrew Dickinson

Bull Case

A diversified HIV and oncology pipeline led by YES2GO, long-acting lenacapavir regimens, Trodelvy expansion, and Anidocel can drive sustained mid- to high-single-digit growth with robust margins and limited LOE risk into the 2030s.

Bear Case

Policy headwinds, competitive pressure in cell therapy and ADCs, execution risk on multiple high-expectation launches (YES2GO, long-acting HIV, Trodelvy, Anidocel), and potential BD missteps could cap growth and compress returns despite a seemingly full pipeline.

Looking Ahead

Investors will be closely watching Gilead Sciences's next quarterly report for continued execution, particularly around yES2GO ramp, 2026 $800M guide, and impact on Descovy PrEP. With operating margins at 37.4%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Gilead Sciences's revenue in Q4 2025?

Gilead Sciences reported Q4 2025 revenue of $7.9B, representing a +4.7% year-over-year change.

Did Gilead Sciences beat earnings expectations in Q4 2025?

The stock rose +5.8% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: A diversified HIV and oncology pipeline led by YES2GO, long-acting lenacapavir regimens, Trodelvy expansion, and Anidocel can drive sustained mid- to high-single-digit growth with robust margins and limited LOE risk into the 2030s.

What is the bull case for GILD stock?

The bull case for GILD centers on: A diversified HIV and oncology pipeline led by YES2GO, long-acting lenacapavir regimens, Trodelvy expansion, and Anidocel can drive sustained mid- to high-single-digit growth with robust margins and limited LOE risk into the 2030s.

What is the bear case for GILD stock?

The bear case for GILD centers on: Policy headwinds, competitive pressure in cell therapy and ADCs, execution risk on multiple high-expectation launches (YES2GO, long-acting HIV, Trodelvy, Anidocel), and potential BD missteps could cap growth and compress returns despite a seemingly full pipeline.

How has GILD stock performed since its Q4 2025 earnings?

GILD moved +5.8% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +18.0% since earnings. Year-to-date, the stock has returned +23.2%.

Browse all 400+ earnings reports →

Learn More

Analyze GILD in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Gilead Sciences and 400+ other stocks, explore the full platform.

Open GILD on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.